Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS011
MIFTS: 60

Plasmacytoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Plasmacytoma

About this section

MalaCards integrated aliases for Plasmacytoma:

Name: Plasmacytoma 12 53 59 55 44 15 73
Solitary Plasmacytoma 12 53 59
Solitary Osseous Plasmacytoma 73
Plasmacytoma - Category 73
Myeloma - Solitary 12
Myeloma, Solitary 12
Solitary Myeloma 12

Characteristics:

Orphanet epidemiological data:

59
plasmacytoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Blood diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare neurological diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:3721
ICD10 33 C90.3 C90.30
MeSH 44 D010954
NCIt 50 C6932 C9349
SNOMED-CT 68 10639003
Orphanet 59 ORPHA86855
MESH via Orphanet 45 D010954
UMLS via Orphanet 74 C0032131
ICD10 via Orphanet 34 C90.2 C90.3
Sources

Summaries for Plasmacytoma

About this section
NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 86855Disease definitionPlasmacytoma is a localized mass of neoplastic monoclonal plasma cells that represents approximately 5% of all plasma cell neoplasms. There are two separate entities: primary plasmacytoma of the bone and extramedullary plasmacytoma of the soft tissues. Of the extramedullary plasmacytomas, 80% occur in the head and neck, usually in the upper respiratory tract. The median age at diagnosis is 50 years and the male to female ratio is 3:1. Long-term survival is possible following local radiotherapy, particularly for soft tissue presentations.Visit the Orphanet disease page for more resources.

MalaCards based summary : Plasmacytoma, also known as solitary plasmacytoma, is related to extramedullary plasmacytoma and solitary osseous plasmacytoma, and has symptoms including bone pain An important gene associated with Plasmacytoma is PVT1 (Pvt1 Oncogene), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, thyroid and colon, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 76 Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within... more...

Sources

Related Diseases for Plasmacytoma

About this section

Diseases related to Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 259)
# Related Disease Score Top Affiliating Genes
1 extramedullary plasmacytoma 33.7 B2M IGKC IL6
2 solitary osseous plasmacytoma 33.2 B2M CD38 CD79A
3 plasma cell neoplasm 31.3 B2M CD38 CD79A IL6 MYC PTPRC
4 myeloma, multiple 31.2 B2M CD38 IL2 IL6 IL6R IRF4
5 b-cell lymphomas 30.0 IRF4 MYC PVT1
6 plasmablastic lymphoma 29.7 CD38 MYC PTPRC
7 lymphoma, mucosa-associated lymphoid type 29.6 CD79A IGKC IRF4
8 monoclonal gammopathy of uncertain significance 29.6 B2M CD38 IL6
9 diffuse large b-cell lymphoma 29.4 CD79A IRF4 MYC
10 leukemia, chronic lymphocytic 29.1 B2M CD38 IL2 PTPRC
11 leukemia, acute myeloid 29.1 CD38 IL2 MYC PTPRC
12 acquired immunodeficiency syndrome 29.0 B2M CD38 IL2 IL6 MYC
13 extramedullary soft tissue plasmacytoma 12.2
14 anaplastic plasmacytoma 12.2
15 solitary plasmacytoma of chest wall 12.2
16 primary plasmacytoma of the bone 12.1
17 lymphoma 10.3
18 papillary conjunctivitis 10.2 IL11 IL6
19 amyloidosis 10.2
20 leukemia 10.2
21 streptococcal toxic-shock syndrome 10.2 IL2 IL6
22 uremic pruritus 10.2 IL2 IL6
23 ovarian lymphoma 10.2 MYC PTPRC
24 poems syndrome 10.2
25 plasma cell leukemia 10.1
26 hodgkin's lymphoma, lymphocytic depletion 10.1 CD79A PTPRC
27 chronic interstitial cystitis 10.1
28 hepatosplenic t-cell lymphoma 10.1
29 osteosclerotic myeloma 10.1 CD79A IL6
30 primary mediastinal large b-cell lymphoma 10.1 IRF4 MYC
31 primary cutaneous anaplastic large cell lymphoma 10.1 IRF4 PTPRC
32 capillary leak syndrome 10.1 IL2 IL6
33 clonorchiasis 10.1 CD79A IL2
34 urinary system disease 10.1 B2M IL2 IL6
35 meningoencephalitis 10.1 B2M CD79A IL6
36 intestinal disease 10.1 IL2 IL6 MYC
37 joint disorders 10.1 IL11 IL6 IL6R
38 autoimmune gastritis 10.1 IL2 IL6
39 lymphoma, hodgkin, classic 10.1 CD79A PTPRC PVT1
40 gastrointestinal system disease 10.1 IL2 IL6 MYC
41 small intestine lymphoma 10.1 B2M CD79A PTPRC
42 kaposi sarcoma 10.1 IL6 IL6ST MYC
43 lymphatic system cancer 10.1 CD79A MYC PTPRC
44 human herpesvirus 8 10.1 IL6 IL6R IL6ST
45 burning mouth syndrome 10.1 IL2 IL6
46 microscopic colitis 10.1 CD79A IL2
47 primary effusion lymphoma 10.1 IL6 IRF4 MYC
48 tonsillitis 10.1 CD79A IL2 IL6
49 preterm premature rupture of the membranes 10.0 IL6 IL6R IL6ST
50 t-cell adult acute lymphocytic leukemia 10.0 IL2 IRF4

Graphical network of the top 20 diseases related to Plasmacytoma:



Diseases related to Plasmacytoma
Sources

Symptoms & Phenotypes for Plasmacytoma

About this section

UMLS symptoms related to Plasmacytoma:


bone pain

GenomeRNAi Phenotypes related to Plasmacytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CD79A EBF1 IL6R IL6ST MYC PTPRC

MGI Mouse Phenotypes related to Plasmacytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 B2M CD38 CD79A EBF1 IL2 IL6
2 hematopoietic system MP:0005397 10.06 B2M CD38 CD79A EBF1 IL2 IL6
3 endocrine/exocrine gland MP:0005379 9.97 B2M CD38 IL2 IL6 IL6R IL6ST
4 homeostasis/metabolism MP:0005376 9.96 B2M CD38 CD79A IL2 IL6 IL6R
5 adipose tissue MP:0005375 9.93 EBF1 IL6 IL6R IL6ST IRF4 MYC
6 immune system MP:0005387 9.9 B2M CD38 CD79A EBF1 IL2 IL6
7 digestive/alimentary MP:0005381 9.88 B2M IL2 IL6 IL6ST MYC PTPRC
8 liver/biliary system MP:0005370 9.61 B2M CD79A EBF1 IL2 IL6 IL6R
9 neoplasm MP:0002006 9.28 B2M CD79A IL2 IL6 IL6R IL6ST
Sources

Drugs & Therapeutics for Plasmacytoma

About this section

Drugs for Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 434)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
5
Lenalidomide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 191732-72-6 216326
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
7
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
8 Ixazomib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1072833-77-2
9
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 56-40-6 750
10 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antilymphocyte Serum Phase 4,Phase 2,Phase 1,Not Applicable
12 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Proteasome Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
36
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
37
Cobalt Approved, Experimental Phase 3,Phase 2 7440-48-4 104729
38
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
39
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
40
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
41
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
42
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
43
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
44
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
45
Idarubicin Approved Phase 3 58957-92-9 42890
46
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
47
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
48
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
49
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
50
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 563)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
3 A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Not yet recruiting NCT03768960 Phase 4 Daratumumab
4 CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
5 High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
6 Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
7 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
8 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
9 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
10 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
11 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
12 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
13 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
14 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
15 Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Completed NCT00432458 Phase 3 Thalidomide;zoledronic acid
16 Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00008229 Phase 3 melphalan
17 Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00002878 Phase 3 dexamethasone;doxorubicin hydrochloride;valspodar;vincristine sulfate
18 Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00049673 Phase 3 prednisone;thalidomide
19 Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Completed NCT00033332 Phase 3 dexamethasone;pamidronate disodium;thalidomide;zoledronic acid
20 Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00017602 Phase 3 dexamethasone
21 Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma Completed NCT00006232 Phase 3 dexamethasone;doxorubicin hydrochloride;idarubicin;vincristine sulfate
22 Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
23 Combination Chemotherapy in Treating Patients With Multiple Myeloma Completed NCT00002678 Phase 3 dexamethasone;melphalan;prednisone
24 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00477971 Phase 3 dexamethasone;melphalan
25 S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma Completed NCT00064038 Phase 3 dexamethasone;lenalidomide
26 Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure Completed NCT00416897 Phase 3 chemotherapy;dexamethasone
27 Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma Completed NCT00813150 Phase 3 Dexamethasone;Bortezomib;Cyclophosphamide
28 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Completed NCT01324947 Phase 3 pomalidomide
29 Velcade (Bortezomib) Consolidation After Transplant Completed NCT01539083 Phase 3 Thalidomide;Bortezomib;Cyclophosphamide;Dexamethasone;Prednisolone
30 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study Completed NCT01311687 Phase 3 pomalidomide;Dexamethasone
31 A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed NCT00424047 Phase 3 CC-5013 plus dexamethasone;Dexamethasone plus Placebo
32 Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone Completed NCT00507416 Phase 3 Bortezomib;Dexamethasone;Melphalan;Prednisone;Thalidomide
33 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Completed NCT00405756 Phase 3 Lenalidomide: Double-blind Induction;Melphalan;Prednisone;Aspirin;Placebo;Lenalidomide: Double-blind Maintenance;Lenalidomide: Open-label
34 UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Completed NCT01621672 Phase 3 Revlimid
35 A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Completed NCT00478777 Phase 3 Lenalidomide;dexamethasone
36 Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma Completed NCT00103506 Phase 3 Bortezomib (VELCADE);Bortezomib (VELCADE);Doxorubicin hydrochloride (DOXIL/CAELYX)
37 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
38 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
39 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
40 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
41 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
42 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
43 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
44 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
45 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
46 Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed NCT01080391 Phase 3 Dexamethasone;Lenalidomide;Carfilzomib
47 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
48 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3 Thalidomide;Dexamethasone
49 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
50 Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma Completed NCT00002556 Phase 3 vincristine sulfate;carmustine;melphalan;cyclophosphamide;prednisone

Search NIH Clinical Center for Plasmacytoma

Cochrane evidence based reviews: plasmacytoma

Sources

Genetic Tests for Plasmacytoma

About this section
Sources

Anatomical Context for Plasmacytoma

About this section

MalaCards organs/tissues related to Plasmacytoma:

41
Bone, Thyroid, Colon, Bone Marrow, B Cells, Lung, T Cells
Sources

Publications for Plasmacytoma

About this section

Articles related to Plasmacytoma:

(show top 50) (show all 1453)
# Title Authors Year
1
A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma. ( 29892544 )
2018
2
Multiple myeloma causing interstitial pulmonary infiltrates and soft-tissue plasmacytoma. ( 29977785 )
2018
3
Extramedullary plasmacytoma. ( 29496243 )
2018
4
Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy. ( 29523615 )
2018
5
Atypical Presentation of Extramedullary Plasmacytoma. ( 29559881 )
2018
6
Tonsillar Plasmacytoma: clues on magnetic resonance imaging. ( 29914385 )
2018
7
Extramedullary plasmacytoma of the trachea: A case report and review of the literature. ( 29504982 )
2018
8
Anaplastic plasmacytoma: a rare tumor presenting as a pathological fracture in a younger adult. ( 29388036 )
2018
9
Plasmacytoma of the Skull-base: A Rare Tumor. ( 29552435 )
2018
10
Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. ( 29692194 )
2018
11
Extramedullary plasmacytoma of the testis: A case report. ( 29204364 )
2018
12
Collet-Sicard Syndrome Attributable to Extramedullary Plasmacytoma of the Jugular Foramen. ( 29191538 )
2018
13
Primary orbital plasmacytoma: An unusual presentation in an adolescent. ( 29567915 )
2018
14
Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. ( 29636948 )
2018
15
Skull base plasmacytoma: A unique case of POEMS syndrome with a plasmacytoma causing craniocervical instability. ( 29100675 )
2018
16
Multicentric plasmacytoma in a harbor porpoise Phocoena phocoena off the coast of Whidbey Island, Washington State, USA. ( 29516861 )
2018
17
Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases. ( 29224044 )
2018
18
CD3<sup>+</sup> CD56<sup>+</sup> EBER1<sup>+</sup> atypical extraosseous plasmacytoma of the nasal cavity. ( 29572766 )
2018
19
Plasmacytoma. ( 29779914 )
2018
20
Testicular plasmacytoma: unique location or circumstantial presentation? ( 29316841 )
2018
21
Late Relapse of Multiple Myeloma with Testicular Plasmacytoma after Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Review of the Literature. ( 29531008 )
2018
22
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. ( 29338789 )
2018
23
Primary extramedullary plasmacytoma of the sigmoid colon with perforation: a case report. ( 29619633 )
2018
24
Testicular plasmacytoma misdiagnosed as orchitis. ( 29866662 )
2018
25
Neurosurgical rare disease: solitary plasmacytoma of the skull - case report and literature review. ( 29940651 )
2018
26
Extramedullary plasmacytoma: rare neoplasm of parotid gland. ( 29301803 )
2018
27
Solitary plasmacytoma of the jaws: therapeutical considerations and prognosis based on a case reports systematic survey. ( 29941386 )
2018
28
Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. ( 29976492 )
2018
29
Breast plasmacytoma with associated amyloidosis mimicking breast carcinoma. ( 30255602 )
2018
30
Colonic CD30 positive plasmablastic plasmacytoma masquerading as anaplastic large cell lymphoma. ( 30098797 )
2018
31
A Case of Multiple Myeloma Associated with Extramedullary Plasmacytoma of the Gallbladder Manifesting as Acute Cholecystitis. ( 30050743 )
2018
32
Solitary extramedullary plasmacytoma of the rectum complicating ulcerative colitis. ( 30238285 )
2018
33
Five cases of orbital extramedullary plasmacytoma: diagnosis and management of an aggressive malignancy. ( 29985709 )
2018
34
Extramedullary Plasmacytoma of the Pancreas Complicated with Left-Sided Portal Hypertension-a Case Report and Literature Review. ( 30033507 )
2018
35
Extramedullary plasmacytoma of the larynx: Literature review and report of a case who subsequently developed acute myeloid leukemia. ( 30127889 )
2018
36
Concomitant Extramedullary Plasmacytoma in the Oropharynx and Hypopharyngeal Squamous Cell Carcinoma. ( 30155331 )
2018
37
Pancreatic Extramedullary Plasmacytoma Presenting as a Pancreatic Mass. ( 30262989 )
2018
38
Solitary Extramedullary Plasmacytoma Mimicking Acute Subdural Hematoma. ( 30268553 )
2018
39
Primary solitary extramedullary plasmacytoma progressing to multiple bone plasmacytomas: a rare condition with therapeutic dilemmas. ( 30335051 )
2018
40
Retroperitoneal extramedullary plasmacytoma: A case report and review of the literature. ( 30431616 )
2018
41
Sudden and unexpected death due to intracranial sellar extramedullary plasmacytoma. ( 30503990 )
2018
42
Intracranial plasmacytoma presenting as glioblastoma multiforme. ( 30025720 )
2018
43
Multiple myeloma with pathologically proven skull plasmacytoma after a mild head injury: Case report. ( 30278508 )
2018
44
Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient. ( 30344143 )
2018
45
A divergent pseudoglandular configuration of cutaneous plasmacytoma in dogs. ( 29153038 )
2018
46
Upregulated plasmacytoma variant translocation 1 promotes cell proliferation, invasion and metastasis in colorectal cancer. ( 29512788 )
2018
47
Dural Plasmacytoma with Meningeal Myelomatosis in a Patient with Multiple Myeloma. ( 29651350 )
2018
48
Solitary Plasmacytoma of Bone of the Spine: Results From Surveillance, Epidemiology, and End Results (SEER) Registry. ( 30005040 )
2018
49
Nasal plasmacytoma: a rare cause of persistent epistaxis. ( 30016897 )
2018
50
Tonsillar plasmacytoma in a dog. ( 30104774 )
2018
Sources

Variations for Plasmacytoma

About this section
Sources

Expression for Plasmacytoma

About this section
Search GEO for disease gene expression data for Plasmacytoma.
Sources

Pathways for Plasmacytoma

About this section

Pathways related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.9 B2M CD79A IL11 IL2 IL6 IL6R
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.17 B2M IL11 IL2 IL6 IL6R IL6ST
3
Human cytomegalovirus infection 37
Show member pathways
 12.92 B2M IL6 IL6R IL6ST MYC
4
Pathways in cancer 37
12.72 IL2 IL6 IL6R IL6ST MYC
5
Immune response NFAT in immune response 22
Show member pathways
 12.51 CD79A IGKC IL2 PTPRC
6
Th17 cell differentiation 37
Show member pathways
 12.38 IL2 IL6 IL6R IL6ST IRF4 MYC
7
T cell receptor signaling pathway 37
Show member pathways
 12.33 IL2 IL6 IRF4 PTPRC
8
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.27 CD79A IRF4 MYC PTPRC
9
NF-kappaB Signaling 4
12.21 B2M CD38 CD79A IL2 IL6ST IRF4
10
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.14 IL2 IL6 IRF4 MYC
11
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12 IL6 IL6R IL6ST
12
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.97 IL11 IL2 IL6 IL6R MYC
13
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.95 IL11 IL6 MYC
14
Th1 Differentiation Pathway 65
Show member pathways
 11.95 IL2 IL6 IL6R IL6ST
15
Adipogenesis 1
11.94 EBF1 IL6 IL6ST
16
Spinal Cord Injury 1
11.89 IL2 IL6 MYC
17
Interleukin-4 and 13 signaling 66
11.87 IL6 IL6R IRF4 MYC
18
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 11.87 IL11 IL2 IL6 IL6R IL6ST MYC
19
Senescence and Autophagy in Cancer 1
11.83 IL6 IL6R IL6ST
20
Hematopoietic cell lineage 37
11.78 CD38 IL11 IL6 IL6R
21
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.75 IL6 IL6R IL6ST IRF4
22
Innate Lymphoid Cell Differentiation Pathways 65
11.7 IL2 IRF4 PTPRC
23
IL6-mediated signaling events 1
Show member pathways
 11.67 IL6 IL6R IL6ST MYC
24
Jak-Stat Signaling Pathway (sino) 67
11.66 IL2 IL6 IL6R IL6ST PTPRC
25
Dendritic Cells Developmental Lineage Pathway 65
11.52 CD38 IL2 IL6 IRF4 PTPRC
26
B Cell Development Pathways 65
11.49 CD38 IL6R PTPRC
27
Hepatitis C and Hepatocellular Carcinoma 1
11.47 IL6 IL6R MYC
28
Interleukin-6 family signaling 66
Show member pathways
 11.47 IL11 IL6 IL6R IL6ST
29
Differentiation Pathway 1
11.43 IL11 IL6 IL6R
30
RAF-independent MAPK1/3 activation 66
Show member pathways
 11.37 IL6 IL6R IL6ST
31
Immune response_IL-6 signaling pathway 22
11.24 IL6 IL6R IL6ST
32
Cytokines and Inflammatory Response 1
11.16 IL11 IL2 IL6
33
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.16 CD38 CD79A IL11 IL2 IL6 PTPRC
Sources

GO Terms for Plasmacytoma

About this section

Cellular components related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 B2M CNTN3 IGKC IL11 IL2 IL6
2 external side of plasma membrane GO:0009897 9.43 B2M CD79A IGKC IL6R IL6ST PTPRC
3 ciliary neurotrophic factor receptor complex GO:0070110 9.16 IL6R IL6ST
4 interleukin-6 receptor complex GO:0005896 8.8 IL6 IL6R IL6ST

Biological processes related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.96 CD38 IL2 IL6 IL6ST MYC
2 positive regulation of MAPK cascade GO:0043410 9.81 IL11 IL6 PTPRC
3 B cell receptor signaling pathway GO:0050853 9.73 CD38 CD79A IGKC PTPRC
4 B cell differentiation GO:0030183 9.72 CD79A IL11 PTPRC
5 positive regulation of osteoblast differentiation GO:0045669 9.69 IL6 IL6R IL6ST
6 response to cytokine GO:0034097 9.67 CD38 IL6R IL6ST
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL11 IL6 IL6R PTPRC
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.65 IL6 IL6R MYC
9 endocrine pancreas development GO:0031018 9.64 IL6 IL6R
10 positive regulation of T cell mediated cytotoxicity GO:0001916 9.64 B2M PTPRC
11 positive regulation of chemokine production GO:0032722 9.63 IL6 IL6R
12 positive regulation of B cell proliferation GO:0030890 9.63 CD38 IL2 PTPRC
13 positive regulation of T cell differentiation GO:0045582 9.62 IL2 PTPRC
14 positive regulation of glial cell proliferation GO:0060252 9.62 IL6 MYC
15 negative regulation of bone resorption GO:0045779 9.61 CD38 IL6
16 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.61 IRF4 PTPRC
17 positive regulation of acute inflammatory response GO:0002675 9.59 IL6 IL6ST
18 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL2 IL6
19 positive regulation of leukocyte chemotaxis GO:0002690 9.58 IL6 IL6R
20 positive regulation of isotype switching to IgG isotypes GO:0048304 9.57 IL2 PTPRC
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 IL2 IL6 IL6R IL6ST
22 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.54 IL6R IL6ST
23 T-helper 17 cell lineage commitment GO:0072540 9.52 IL6 IRF4
24 interleukin-6-mediated signaling pathway GO:0070102 9.5 IL6 IL6R IL6ST
25 positive regulation of cell proliferation GO:0008284 9.5 CD38 IL11 IL2 IL6 IL6R IL6ST
26 positive regulation of T cell proliferation GO:0042102 9.46 IL2 IL6 IL6ST PTPRC
27 hepatic immune response GO:0002384 9.4 IL6 IL6R
28 cytokine-mediated signaling pathway GO:0019221 9.17 IL11 IL2 IL6 IL6R IL6ST IRF4
29 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 EBF1 IL11 IL2 IL6 IRF4 MYC

Molecular functions related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL11 IL2 IL6 IL6R
2 ciliary neurotrophic factor receptor activity GO:0004897 9.32 IL6R IL6ST
3 interleukin-6 binding GO:0019981 9.16 IL6R IL6ST
4 interleukin-6 receptor activity GO:0004915 8.96 IL6R IL6ST
5 interleukin-6 receptor binding GO:0005138 8.8 IL6 IL6R IL6ST
Sources

Sources for Plasmacytoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....